Gene "AHI1"
Found 4 records
Gene information
Gene symbol:
AHI1
See related:
Ensembl: ENSG00000135541, Gene ID: 54806
Additive variants :
Detected
Genetic interaction partners
Confidence      Stringent (ε>0.16 or ε<-0.12)      Intermediate (-0.16≤ε≤-0.08 or 0.08≤ε≤0.16)      Lenient (|ε|<0.08)
Positive interactions
  • ELOVL1 
  • ZFP42 
  • RPL13 
  • NSUN5 
  • CTU1 
  • ELP1 
  • ARHGAP11A 
  • NRAS 
  • VPS35 
  • PPP2R5C 
  • PSMA4 
  • PDCD6IP 
  • GOLPH3L 
  • PTPRN2 
  • RHOT2 
  • SLC27A3 
  • CLPX 
  • RPL4 
  • MIOS 
  • TBL1XR1 
  • SORT1 
  • RANGRF 
  • LSM1 
  • ALDH1L2 
  • RPL29 
  • VAPB 
  • DGAT1 
  • PEX5L 
  • RPL34 
  • XPO5 
  • PRDX6 
  • NTHL1 
  • ARL9 
  • PLPP4 
  • DNAJA3 
  • ACAA1 
  • SLC25A32 
  • TGS1 
  • SNX7 
  • PICALM 
  • PPAN 
  • MEF2A 
  • CERK 
  • PGD 
  • RMND5B 
  • PDK2 
  • ASNA1 
  • MTHFR 
  • LTA4H 
  • PHB2 
  • SMARCB1 
  • CTSE 
  • SC5D 
  • GLUD2 
  • KIF2C 
  • CS 
  • RPL9 
  • TRMU 
  • ABCG2 
  • NRDC 
  • PRKCSH 
  • AKT1 
  • COPS5 
  • ZDHHC17 
  • ACER3 
  • RPL10A 
  • SUCO 
  • ANKRD11 
  • APIP 
  • TM9SF3 
  • SORT1 
  • TDP1 
  • SLC12A8 
  • HIST2H4B 
  • SELENOO 
  • PITRM1 
  • RPS9 
  • VDAC2 
  • DPH6 
  • WDR1 
  • CHIA 
  • RTN4IP1 
  • AGPAT4 
  • BMP2K 
Negative interactions
  • MRM2 
  • ATP1A1 
  • VPS41 
  • BBOX1 
  • RPS6 
  • BIN3 
  • ADA 
  • RPS16 
  • KIAA1109 
  • RPS18 
  • VAMP2 
  • PTRH1 
  • WDR48 
  • TOM1 
  • CHN1 
  • SLC35B1 
  • LIPT1 
  • SIN3A 
  • UXS1 
  • MRE11 
  • DMXL1 
  • PRKAG2 
  • COX6B2 
  • PRKD1 
  • PPAN 
  • ASH1L 
  • HGS 
  • HSPA4L 
  • TRIP12 
  • SCPEP1 
  • TMED9 
  • BRDT 
  • VRK1 
  • USP10 
  • ARL1 
  • CHMP1A 
  • LIPT2 
  • CCNA2 
  • TOM1 
  • RPSA 
  • PPME1 
  • PAPSS1 
  • TRIT1 
  • ALG8 
  • DDI2 
  • ABCC6 
  • RPL7A 
  • DDX11 
  • CRLS1 
  • CAMKK2 
  • METTL1 
  • SURF4 
  • EP400 
  • UPF2 
  • TBC1D30 
  • CACNA1D 
  • RPS21 
  • IAH1 
  • HAT1 
  • DPYSL2 
  • PPP2CB 
  • MAD2L1 
  • NMNAT1 
  • LETM1 
  • SLC25A44 
  • YOD1 
  • POMT2 
  • HSPA4L 
  • RBM22 
  • LDHD 
  • RPS11 
  • TCF25 
  • PHGDH 
  • PFAS 
  • WDR76 
  • GDA 
  • CTPS1 
  • ECHDC2 
  • OSBPL10 
  • NIT2 
  • TST 
  • ECHDC2 
  • TVP23B 
  • QPRT 
Modifier statisitcs
Record:
Disorder:
Vriant:
Reference:
Effect type:
Expressivity(4)  
Modifier effect:
Altered severity(3) ,Altered sensorimotor symptoms(1)  
Details:
  • Variant 1:
    Gene:
    Genomic location:
    dbSNP ID:
    Target disease:
    Effect type:
    Expressivity 
    Modifier effect:
    Altered severity 
    Evidence:
    Assessment of genotype–phenotype associations 
    Effect:
    These two AHI1 mutations might thus represent neurological modifiers of CEP290-related disease
    Reference:
    Title:
    Genetic screening of LCA in Belgium: predominance of CEP290 and identification of potential modifier alleles in AHI1 of CEP290-related phenotypes.
    Species studied:
    Human
    Abstract:
    Leber Congenital Amaurosis (LCA), the most severe inherited retinal dystrophy, is genetically heterogeneous, with 14 genes accounting for 70% of patients. Here, 91 LCA probands underwent LCA chip analysis and subsequent sequencing of 6 genes (CEP290, CRB1, RPE65, GUCY2D, AIPL1and CRX), revealing mutations in 69% of the cohort, with major involvement of CEP290 (30%). In addition, 11 patients with early-onset retinal dystrophy (EORD) and 13 patients with Senior-Loken syndrome (SLS), LCA-Joubert syndrome (LCA-JS) or cerebello-oculo-renal syndrome (CORS) were included. Exhaustive re-inspection of the overall phenotypes in our LCA cohort revealed novel insights mainly regarding the CEP290-related phenotype. The AHI1 gene was screened as a candidate modifier gene in three patients with the same CEP290 genotype but different neurological involvement. Interestingly, a heterozygous novel AHI1 mutation, p.Asn811Lys, was found in the most severely affected patient. Moreover, AHI1 screening in five other patients with CEP290-related disease and neurological involvement revealed a second novel missense variant, p.His758Pro, in one LCA patient with mild mental retardation and autism. These two AHI1 mutations might thus represent neurological modifiers of CEP290-related disease.
  • Gene:
    Genomic location:
    chr6:135751024
    dbSNP ID:
    Alias:
    AHI1:rs13312995
    Target disease:
    Joubert syndrome(Orphanet_475)
    Effect type:
    Expressivity 
    Modifier effect:
    Altered severity 
    Evidence:
    Significantly higher frequency than in healthy control subjects (P<0.001) and in patients with nphp1 mutations without neurologic symptoms (P<0.002) 
    Effect:
    Epistatic effects that are provided by heterozygous NPHP6 and AHI1 mutations and variants may contribute to the appearance of extrarenal symptoms in patients with NPHP1 mutations.
    Reference:
    Title:
    High NPHP1 and NPHP6 mutation rate in patients with Joubert syndrome and nephronophthisis: potential epistatic effect of NPHP6 and AHI1 mutations in patients with NPHP1 mutations.
    Species studied:
    Human
    Abstract:
    Joubert syndrome (JS) is an autosomal recessive disorder that is described in patients with cerebellar ataxia, mental retardation, hypotonia, and neonatal respiratory dysregulation. Kidney involvement (nephronophthisis or cystic renal dysplasia) is associated with JS in one fourth of known cases. Mutations in three genes--AHI1, NPHP1, and NPHP6--have been identified in patients with JS. However, because NPHP1 mutations usually cause isolated nephronophthisis, the factors that predispose to the development of neurologic involvement are poorly understood. In an attempt to identify such genetic determinants, a cohort of 28 families with nephronophthisis and at least one JS-related neurologic symptom were screened for mutations in AHI1, NPHP1, and NPHP6 genes. NPHP1 and NPHP6 homozygous or compound heterozygous mutations were found in 13 (46%) and six (21%) unrelated patients, respectively. Two of the 13 patients with NPHP1 mutations carried either a heterozygous truncating mutation in NPHP6 or a heterozygous missense mutation in AHI1. Furthermore, five patients with NPHP1 mutations carried the AHI1 variant R830W, which was predicted to be possibly damaging and was found with significantly higher frequency than in healthy control subjects and in patients with NPHP1 mutations without neurologic symptoms (five of 26 versus four of 276 and three of 152 alleles; P < 0.001 and P < 0.002, respectively). In contrast to the variable neurologic and milder retinal phenotype of patients with NPHP1 mutations, patients with NPHP6 mutations presented with a more severe neurologic and retinal phenotype. In conclusion, NPHP1 and NPHP6 are major genes of nephronophthisis associated with JS. Epistatic effects that are provided by heterozygous NPHP6 and AHI1 mutations and variants may contribute to the appearance of extrarenal symptoms in patients with NPHP1 mutations.
  • Gene:
    Genomic location:
    chr6:135751024
    dbSNP ID:
    Alias:
    AHI1:rs13312995
    Target disease:
    Nephronophthisis(DOID_12712)
    Effect type:
    Expressivity 
    Modifier effect:
    Altered sensorimotor symptoms 
    Evidence:
    Pedigree analysis 
    Effect:
    AHI1 is required for photoreceptor outer segment development and is a modifier for retinal degeneration in nephronophthisis
    Reference:
    Title:
    AHI1 is required for photoreceptor outer segment development and is a modifier for retinal degeneration in nephronophthisis.
    Species studied:
    Human
    Abstract:
    Degeneration of photoreceptors is a common feature of ciliopathies, owing to the importance of the specialized ciliary structure of these cells. Mutations in AHI1, which encodes a cilium-localized protein, have been shown to cause a form of Joubert syndrome that is highly penetrant for retinal degeneration. We show that Ahi1-null mice fail to form retinal outer segments and have abnormal distribution of opsin throughout their photoreceptors. Apoptotic cell death of photoreceptors occurs rapidly between 2 and 4 weeks of age in these mice and is significantly (P = 0.00175 and 0.00613) delayed by a reduced dosage of opsin. This phenotype also shows dosage-sensitive genetic interactions with Nphp1, another ciliopathy-related gene. Although it is not a primary cause of retinal blindness in humans, we show that an allele of AHI1 is associated with a more than sevenfold increase in relative risk of retinal degeneration within a cohort of individuals with the hereditary kidney disease nephronophthisis. Our data support context-specific roles for AHI1 as a contributor to retinopathy and show that AHI1 may explain a proportion of the variability in retinal phenotypes observed in nephronophthisis.
  • Gene:
    Genomic location:
    chr6:135751079
    dbSNP ID:
    Target disease:
    Effect type:
    Expressivity 
    Modifier effect:
    Altered severity 
    Evidence:
    Assessment of genotype–phenotype associations 
    Effect:
    These two AHI1 mutations might thus represent neurological modifiers of CEP290-related disease
    Reference:
    Title:
    Genetic screening of LCA in Belgium: predominance of CEP290 and identification of potential modifier alleles in AHI1 of CEP290-related phenotypes.
    Species studied:
    Human
    Abstract:
    Leber Congenital Amaurosis (LCA), the most severe inherited retinal dystrophy, is genetically heterogeneous, with 14 genes accounting for 70% of patients. Here, 91 LCA probands underwent LCA chip analysis and subsequent sequencing of 6 genes (CEP290, CRB1, RPE65, GUCY2D, AIPL1and CRX), revealing mutations in 69% of the cohort, with major involvement of CEP290 (30%). In addition, 11 patients with early-onset retinal dystrophy (EORD) and 13 patients with Senior-Loken syndrome (SLS), LCA-Joubert syndrome (LCA-JS) or cerebello-oculo-renal syndrome (CORS) were included. Exhaustive re-inspection of the overall phenotypes in our LCA cohort revealed novel insights mainly regarding the CEP290-related phenotype. The AHI1 gene was screened as a candidate modifier gene in three patients with the same CEP290 genotype but different neurological involvement. Interestingly, a heterozygous novel AHI1 mutation, p.Asn811Lys, was found in the most severely affected patient. Moreover, AHI1 screening in five other patients with CEP290-related disease and neurological involvement revealed a second novel missense variant, p.His758Pro, in one LCA patient with mild mental retardation and autism. These two AHI1 mutations might thus represent neurological modifiers of CEP290-related disease.